Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 23, No 2 (January 10), 2005: pp. 311-323
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.04.058

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lerman, C.
Right arrow Articles by Berrettini, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lerman, C.
Right arrow Articles by Berrettini, W.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

REVIEW ARTICLE

Treating Tobacco Dependence: State of the Science and New Directions

Caryn Lerman, Freda Patterson, Wade Berrettini

From the Abramson Cancer Center, Center for Neurobiology and Behavior, Annenberg Public Policy Center, University of Pennsylvania Health System, Philadelphia, PA

Address reprint requests to Caryn Lerman, PhD, Tobacco Use Research Center, 3535 Market St, Suite 4100, Philadelphia, PA 19104; e-mail: clerman{at}mail.med.upenn.edu.

Despite almost two decades of intensive tobacco control efforts, nearly one quarter of Americans continue to smoke. The two United States Food and Drug Administration–approved medications used to treat tobacco dependence, bupropion and nicotine replacement therapy, are effective for only a fraction of smokers. Investigations of medications approved for affective disorders and other forms of substance abuse, such as fluoxetine and naltrexone, have yielded mixed results as tobacco dependence treatments. A particular challenge in tobacco dependence treatment is the development of effective approaches for smokers with unique needs, such as cancer patients and pregnant women. Despite new developments in these areas, significant gaps in knowledge and practice remain. Basic research in the neurobiologic and genetic basis of nicotine dependence offers promise for the development of novel and more effective treatment approaches. For example, emerging research in pharmacogenetics explores how genetic variation in drug-metabolizing enzymes and drug targets modifies response to pharmacotherapy. These discoveries could someday help practitioners to individualize the type, dosage, and duration of tobacco dependence treatment based on genotype, and maximize the efficacy.

Supported by a Transdisiciplinary Tobacco Use Research Center Grant P5084718 from the National Cancer Institute and National Institute on Drug Abuse.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Health Educ ResHome page
A. H. Levinson, R. E. Glasgow, B. Gaglio, T. L. Smith, J. Cahoon, and A. C. Marcus
Tailored behavioral support for smoking reduction: development and pilot results of an innovative intervention
Health Educ. Res., April 1, 2008; 23(2): 335 - 346.
[Abstract] [Full Text] [PDF]


Home page
AMERICAN JOURNAL OF LIFESTYLE MEDICINEHome page
K. M . Sullivan, S. M. Seed, and R. J. DeBellis
State of the Art Reviews: Smoking Cessation: A Review of Treatment Considerations
American Journal of Lifestyle Medicine, May 1, 2007; 1(3): 201 - 213.
[Abstract] [PDF]


Home page
Am J EpidemiolHome page
K. Sheikh
RE: "CIGARETTE SMOKING AND INCIDENCE OF FIRST DEPRESSIVE EPISODE: AN 11-YEAR, POPULATION-BASED FOLLOW-UP STUDY"
Am. J. Epidemiol., November 1, 2006; 164(9): 918 - 919.
[Full Text] [PDF]


Home page
J PsychopharmacolHome page
A. M. Lee and R. F. Tyndale
Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment
J Psychopharmacol, July 1, 2006; 20(4_suppl): 7 - 14.
[Abstract] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C. H. Halbert, O. H. Gandy Jr., A. Collier, and L. Shaker
Intentions to Participate in Genetics Research among African American Smokers
Cancer Epidemiol. Biomarkers Prev., January 1, 2006; 15(1): 150 - 153.
[Abstract] [Full Text] [PDF]


Home page
CA Cancer J ClinHome page
J. E. Henningfield, R. V. Fant, A. R. Buchhalter, and M. L. Stitzer
Pharmacotherapy for Nicotine Dependence
CA Cancer J Clin, September 1, 2005; 55(5): 281 - 299.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. C. Gotay
Behavior and Cancer Prevention
J. Clin. Oncol., January 10, 2005; 23(2): 301 - 310.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
B. W. Stewart and A. S. Coates
Cancer Prevention: A Global Perspective
J. Clin. Oncol., January 10, 2005; 23(2): 392 - 403.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online